MabVax links with Memorial Sloan Kettering and Juno on anti-cancer therapeutics

11 September 2014

Clinical stage oncology drug development company MabVax Therapeutics (OTCQB: TELK) has entered agreements with Memorial Sloan Kettering and Juno Therapeutics for the development of new therapeutics using antibody-targeting sequences derived from the fully-human antibodies discovered using MabVax’ antibody discovery platform.

MabVax will supply targeting sequences from the fully-human antibodies to Memorial Sloan Kettering, and researchers at MSK will conduct early-stage research and development of chimeric antigen receptor (CAR) T-cell therapeutics using the MabVax antibody sequences. They will be tested both in vitro and in animal models with the purpose of producing anti-cancer therapeutics targeting certain solid tumors.

Under an exclusive option agreement between MabVax and Juno, the latter will have the right to negotiate a license agreement for exclusive rights to any CAR T-cell therapeutic products using the antibody sequences provided to MSK.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK